Abstract 77P
Background
Sexual dysfunction is of the most common late effects after cancer. Normative general population data on sexual health is essential for supporting the interpretation of patient-reported outcomes (PROMs) in cancer studies and clinical practice and can contribute to improve survivorship care. This study aims to provides age-, sex- and morbidity specific Norwegian normative values for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires; the Sexual Health Questionnaire QLQ-SHQ22, and the sexual domains of the breast modules QLQ-BR23/QLQ-BR45 inindividuals with and without history of cancer.
Methods
A nationwide general population sample stratified by sex and age (18–29, 30–39, 40–49, 50–59, 60–69, 70-79 years) was drawn from the Norwegian Population Register. Participants were notified through National online health services and postal mail. The survey included sociodemographic background, morbidity assessed bythe Self-Administered Comorbidity Questionnaire and sexual health assessed by the sexual health EORTC questionnaires.
Results
Of the 15,627 eligible individuals, 5,135 (33%) responded. Among these, 453 persons reported being diagnosed one or several times with cancer, and 4669 persons had no former history of cancer (breast, prostate, gynecological and others). Individuals with cancer scored significantly lower (p<0.01) on several functional scales: libido (scores 54 vs. 70), sexual functioning (45 vs 58), sexual enjoyment (67 vs 76), and for women femininity (65 vs. 84). The most prominent differences in symptoms were fatigue (32 vs 20) and worry of incontinence (27 vs. 9). Women and individuals with comorbidities had in general poorer sexual health, and differences were most pronounced in the youngest age groups.
Conclusions
The present study is the first to use normative EORTC data to compare sexual health in individuals with- and without cancer. Sexual health was in general significantly poorer in individuals with history of cancer compared to individuals without cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Randi Johansen Reidunsdatter.
Funding
Norwegian Cancer Society and Norwegian Breast Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
28P - Xanthine oxidase as a prognostic factor in colorectal cancer metastatic disease
Presenter: Anton Burlaka
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09